Mr. Brook Riggins reports

THIOGENESIS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

Thiogenesis Therapeutics Corp. will undertake a non-brokered private placement of up to 16 million common shares of the company at a price of 50 cents per common share for gross proceeds of $8-million.

This offering is subject to the approval of the TSX Venture Exchange. The company anticipates closing of the offering by the end of May subject to receipt of all necessary regulatory approvals. Upon issuance, the offered shares will be subject to a four-month-and-one-day hold period pursuant to securities laws in Canada and, where applicable, exchange policies.

In connection with the offering, the company may pay finders' fees to eligible persons in compliance with applicable securities laws and exchange policies. The proceeds of the financing will be used to support the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a phase 2 clinical study in Leigh syndrome, together with formulation and manufacturing activities, regulatory engagement, and general working capital and corporate purposes.

About Thiogenesis Therapeutics Corp.

Based in San Diego, Calif., Thiogenesis is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to offer improved tolerability and dosing compared with existing therapies. The company is advancing TTI-0102 toward a pivotal phase 3 clinical trial in nephropathic cystinosis and is supporting clinical development in inherited mitochondrial diseases, following completion of a phase 2 program in MELAS and the initiation of a phase 2 clinical study in Leigh syndrome.

We seek Safe Harbor.